spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Factor VIIa 

 HSMN NewsFeed - 21 Feb 2023
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Apr 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2016
OPKO Health to Acquire Transition Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2016
Savara Pharmaceuticals Acquires Serendex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2012
Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 17 Apr 2012
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2011
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Aug 2010
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2010
GTC Biotherapeutics Announces New $7 Million Financing, Company Restructuring and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2009
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2008
Catalyst Biosciences Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Jul 2008
Bayer HealthCare and Maxygen Announce Hematology Agreement
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 13 May 2008
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Mar 2008
Maxygen Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2008
LFB Biotechnologies to Collaborate with GTC Biotherapeutics on Coagulation Factor IX Program
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Dec 2007
GTC Obtains FDA Orphan Drug Designation For ATryn(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2007
Maxygen Announces Plans to Consolidate Operations in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
Maxygen Updates Status of MAXY-alpha Program
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2007
GTC Obtains FDA Fast Track Designation for ATryn(R) and Permission to Submit a Rolling BLA
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2007
Nuvelo Resumes Development of Alfimeprase in Multiple Blood-Clot Related Indications
Biopharmaceuticals
 HSMN NewsFeed - 27 Mar 2007
Nuvelo Receives FDA Fast Track Status for rNAPc2 in Both First- and Second-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jan 2007
ATryn(R) Market Authorization Transferred To LEO Pharma A/S
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Nuvelo Announces Presentations on Alfimeprase and rNAPc2 at The American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Oct 2006
NovoSeven(R) Becomes First and Only Recombinant Therapy for Treatment of Rare, Life-Threatening Bleeding Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2006
GTC Biotherapeutics and LFB Biotechnologies Enter Strategic Collaboration for Recombinant Plasma Proteins and Monoclonal Antibodies
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2006
Nuvelo Appoints H. Ward Wolff as Chief Financial Officer and Jill M. Pergande as Vice President, Human Resources
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2006
Nuvelo Announces Publication of Phase 2 Alfimeprase Study Results in Central Venous Catheter Occlusion
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
Nuvelo Expands Depth in Manufacturing and Development With Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2006
Nuvelo Announces Completion of Phase 2 Heparin Replacement Trial Evaluating rNAPc2 in Acute Coronary Syndromes
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 May 2006
Maxygen Achieves Milestone in Alliance with Roche for Factor VIIa Therapeutics
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 31 additional stories matching:
Factor VIIa
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.